Systemic and metabolic conditions such as diabetes, obesity, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, ankylosing spondylitis, as well as Alzheimers disease, Parkinsons disease, chronic depression and autism spectrum disorders also become a growing health problem [1,2,3,4,5,6]
The Middle East and Africa held a 2% share of the market in 2025 and are expected to grow at a notable CAGR of 14.8% during the projection period, driven by expanding healthcare investments and obesity management programs
Novo Nordisk, the manufacturer of Ozempic and Wegovy, petitioned the FDA to remove semaglutide from the shortage list, arguing that production and supply levels had sufficiently stabilized
Rimbara, E., Mori, S., Kim, H
This is why many users report that after 3 to 5 months: Sleep quality declines Fat loss slows or stops Energy levels drop Results plateau In some cases, biomarkers such as IGF-1 can even fall below baseline after prolonged overstimulation
It is also possible that GLP-1RAs may have a therapeutic effect across traditional diagnostic categories
/media/img/mt/2024/10/GLP_1/original.jpg){kind=icon}
